NCT01451684

Brief Summary

This is an observational study to aid in the development of a non-invasive prenatal test that may be used to aid in detection of fetal aneuploidy. Pregnant women will be recruited and asked to provide a blood sample to be used for general test development purposes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2011

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2011

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

October 10, 2011

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 14, 2011

Completed
8.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2019

Completed
Last Updated

April 30, 2020

Status Verified

April 1, 2020

Enrollment Period

8.5 years

First QC Date

October 10, 2011

Last Update Submit

April 28, 2020

Conditions

Keywords

pregnancyfetuseuploid

Outcome Measures

Primary Outcomes (1)

  • Absence of chromosomal abnormality

    At time of enrollment

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

This study will include women who have a healthy pregnancy.

You may qualify if:

  • Subject has singleton or twin pregnancy confirmed via evaluation by a healthcare provider
  • Subject is able to provide informed consent
  • Subject is ≥ 18 years of age
  • Subject is at least 10 weeks gestation for general enrollment
  • Subject has no known risk factors for chromosomal abnormalities of the fetus
  • Subject has no suspected or confirmed fetal abnormalities

You may not qualify if:

  • Subject is pregnant with more than two fetuses
  • Subject is unwilling to undergo a blood draw

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ariosa Diagnostics

San Jose, California, 95138, United States

Location

Study Officials

  • Tracy Roberts

    Ariosa Diagnostics

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR INVESTIGATOR
PI Title
CRA

Study Record Dates

First Submitted

October 10, 2011

First Posted

October 14, 2011

Study Start

June 1, 2011

Primary Completion

December 1, 2019

Study Completion

December 1, 2019

Last Updated

April 30, 2020

Record last verified: 2020-04

Locations